Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
130 hedge funds and large institutions have $2.08B invested in Karuna Therapeutics, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 61 increasing their positions, 22 reducing their positions, and 8 closing their positions.
388% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 8
177% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 22
73% more capital invested
Capital invested by funds: $1.2B → $2.08B (+$880M)
31% more funds holding
Funds holding: 99 → 130 (+31)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
72% less call options, than puts
Call options by funds: $3.02M | Put options by funds: $10.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51M |
| 2 |
State Street
Boston,
Massachusetts
|
+$46.4M |
| 3 |
BlackRock
New York
|
+$27.7M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$24.2M |
| 5 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$39.4M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$16.1M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$12.8M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$8.12M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.64M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PHK
126
Point72 Hong Kong
Hong Kong
| $8K | +$6.52K | +75 | New |
|
|
MAM
127
Meeder Asset Management
Dublin,
Ohio
| $2K | -$6.78K | -78 | -80% |
|
|
IFAM
128
Institutional & Family Asset Management
Fort Collins,
Colorado
| $2K | +$174 | +2 | +14% |
|
|
PCG
129
Private Capital Group
West Hartford,
Connecticut
| $1K | +$869 | +10 | New |
|
|
VC
130
Vivo Capital
Palo Alto,
California
| – | -$16.1M | -223,692 | Closed |
|
|
LGM
131
Logos Global Management
San Francisco,
California
| – | -$5.01M | -69,658 | Closed |
|
132
Renaissance Technologies
New York
| – | -$2.02M | -28,000 | Closed |
|
133
Victory Capital Management
San Antonio,
Texas
| – | -$292K | -4,056 | Closed |
|
134
Simplex Trading
Chicago,
Illinois
| – | -$153K | -1,762 | -78% |
|
135
Marshall Wace
London,
United Kingdom
| – | -$74K | -1,034 | Closed |
|
|
PCM
136
Pinz Capital Management
New York
| – | -$41K | -573 | Closed |
|
137
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -48 | Closed |
|
138
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$1K | -9 | Closed |
|
KRTX Hedge Fund Activity: Q2 2020 in Review
130 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q2 2020, worth a combined $2.08B — up 73% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new KRTX positions and 8 closed out — a net gain of 31 holders — while 61 added to existing stakes and 22 trimmed.
The largest buyer was Vanguard Group, adding an estimated $51M. The largest seller was T. Rowe Price Associates, cutting an estimated $39.4M.
- 130 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q2 2020, up from 99 in Q1 2020.
- Funds reported $2.08B of Karuna Therapeutics, Inc. Common Stock stock for Q2 2020, up 73% quarter-over-quarter.
- 39 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q2 2020 and 8 closed out, a net change of +31 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q2 2020 was Vanguard Group, an estimated $51M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q2 2020 was T. Rowe Price Associates, an estimated $39.4M sold.
Based on aggregated 13F filings for Q2 2020.